The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
Journal Title: OncoReview - Year 2017, Vol 7, Issue 2
Abstract
Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objective: The evaluation of the efficacy and toxicity of TKI drugs in NSCLC patients treated in single centre. Material and methods: NSCLC patients treated with TKI (gefitinib, erlotynib, afatinib) between 2012– 2016 were retrospectively analysed. We evaluated: overall response rate (ORR) which is the sum of complete responses (CR) and partial remissions (PR), progression free survival (PFS), overall survival (OS) and adverse events (AE) according to CTCAE (Common Terminology Criteria for Adverse Events) scale. Results: The study group were 16 patients ORR was 50% (CR: 1, PR: 7). Median PFS and OS was 8,7 and 22,9 months respectively. Adverse events observed mainly in stage 1 and 2 were related to hyponatraemia, hyperbilirubinemia, skin toxicity and mucositis. There was one death reported due to infectious complications. Conclusion: The efficacy and toxicity of TKI in study group were found to be similar to those described in the literature.
Authors and Affiliations
Joanna Kardas, Agnieszka Buraczewska, Paweł Chrom, Waśko-Grabowska Anna, Beata Młot, Cezary Szczylik
Keywords
Related Articles
- EP ID EP189867
- DOI 10.24292/01.OR.300617.7
- Views 220
- Downloads 0
Nefrotoksyczność leków stosowanych w chemioterapii nowotworów
Rozwój onkologii klinicznej oraz coraz częstsza zapadalność na nowotwory powodują szybkie zwiększanie się grupy chorych leczonych chemioterapeutykami. Stosowanie tych leków oprócz korzyści niesie ze sobą również ryzyko w...
Targeted therapies for chronic myeloid leukemia and cardiovascular system
Morbidity of chronic myeloid leukemia is recorded in elderly population, in patients with coexisting significant risk factors for atherosclerosis and heart diseases. Molecularly targeted therapy, imatinib, dasatinib and...
Tyrosine kinase inhibitors in hematologic malignancy: should we be concerned?
Cardiovascular concerns from radiation therapy and other radiation exposure
Nowe spojrzenie na ocenę skuteczności terapii celowanych zaawansowanego raka nerki– kontrowersje
W ciągu ostatnich kilku lat daje się zaobserwować zdecydowany rozwój nowoczesnych terapii stosowanych w leczeniu zaawansowanego/ rozsianego raka nerki, związany przede wszystkim z poznaniem podstaw molekularnych raka ner...